問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Others-

Division of Obstetrics & Gynecology

Division of Radiology

Division of Urology

Division of Radiation Therapy

更新時間：2023-09-19

沈書慧
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

47Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

沈書慧

List

98Cases

2022-06-01 - 2024-10-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-06-25 - 2024-01-04

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-06-03 - 2030-04-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-02-03 - 2033-05-03

Phase II/III

Active
一項第 II/III 期、開放性、跨國、多中心、隨機分配試驗，在 [177Lu]Lu-PSMA 精準放射標靶療法期間或之後惡化的 PSMA 陽性轉移性去勢抗性前列腺癌成人參與者中，比較 AAA817 相較於標準照護的治療

  • Condition/Disease

    PSMA-positive metastatic castration-resistant prostate cancer

  • Test Drug

    AAA817

Participate Sites
4Sites

Recruiting4Sites

2024-02-12 - 2030-07-31

Phase II/III

Active
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • Condition/Disease

    Solid Cancer

  • Test Drug

    Raludotatug Deruxtecan (R-DXd)

Participate Sites
6Sites

Recruiting5Sites

Suspended1Sites

2025-11-01 - 2033-12-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)

  • Condition/Disease

    Endometrial Cancer

  • Test Drug

    Frozen Crystal Injection Injection

Participate Sites
5Sites

Not yet recruiting5Sites

2025-03-01 - 2032-01-31

Phase III

Active
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112)

  • Condition/Disease

    Ovarian Cancer

  • Test Drug

    Frozen Crystal Injection

Participate Sites
7Sites

Recruiting7Sites

2020-10-16 - 2028-06-26

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-05-19 - 2027-01-25

Phase III

Active
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer

  • Condition/Disease

    Muscle- Invasive Bladder Cancer

  • Test Drug

    BMS-986205

Participate Sites
4Sites

Recruiting4Sites

1 4 5 6 7 8 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB